Application of CRISPR/Cas9 in Treating Hepatitis B Virus
Journal of Liver Cancer
; : 111-116, 2017.
Article
Dans En
| WPRIM
| ID: wpr-120522
Responsable en Bibliothèque :
WPRO
ABSTRACT
The advent of oral antiviral agents has revolutionized hepatitis B treatment. It has led to decreased incidence and mortality related to hepatocellular carcinoma. However, although nucleos(t)ide analogs (NA) are fast and potent in inhibiting hepatitis B virus (HBV) polymerase and reverse transcriptase activity, complete cure of the virus is not possible. The complete eradication of HBV requires the covalently-closed-circular DNA (cccDNA) to be eliminated. Novel gene editing methods, such as zing finger nucleases, transcription activator-like effector nucleases, and the clustered regularly interspaced short palindromic repeats/Cas9 (CRISPR/Cas9) system, designed to target specific DNA sequences has great potential for therapeutic application. Among these, the CRISPR/Cas9 system may be the most feasible approach to eradicate HBV cccDNA. Further studies are needed to develop a more efficient and safer method of delivery using the CRISPR/Cas9 system to achieve complete cure of chronic hepatitis B.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Antiviraux
/
ADN
/
ADN circulaire
/
Séquence nucléotidique
/
Virus de l'hépatite B
/
Incidence
/
Mortalité
/
RNA-directed DNA polymerase
/
Carcinome hépatocellulaire
/
Hépatite B chronique
Type d'étude:
Incidence_studies
/
Prognostic_studies
langue:
En
Texte intégral:
Journal of Liver Cancer
Année:
2017
Type:
Article